Werewolf Therapeutics Inc (HOWL) is a Healthcare · Biotechnology company listed on NASDAQ. Price $0.99 (+3.15%), Market cap $0.02B, 52-week low–high $0.43 ~ $2.19.
Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of advanced or m
Financial statements, price targets, institutional (13F) holdings and related news for Werewolf Therapeutics Inc are updated in real time on BlackAll Trade.
Werewolf Therapeutics Inc trades at $0.99 (+3.15%). Real-time quotes and charts are available on BlackAll Trade.
Werewolf Therapeutics Inc has a market cap of about $0.02B.
Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-media